Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
survodutide + metformin
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous
01
Overview
BI 1815368 is a fixed-dose combination (FDC) therapy under development by Boehringer Ingelheim, comprising survodutide (BI 456906) and metformin. Survodutide is a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), designed to mimic the natural hormone oxyntomodulin. By targeting both receptors, it aims to suppress appetite and increase energy expenditure. Metformin is a biguanide that lowers blood glucose by inhibiting hepatic gluconeogenesis and improving peripheral insulin sensitivity, primarily through the activation of AMP-activated protein kinase (AMPK). The combination is being evaluated in Phase 2 clinical trials for the treatment of type 2 diabetes and obesity, potentially offering enhanced glycemic control and weight loss compared to monotherapy.
- Other names
- survodutide/metforminBI 1815368 + metforminsurvodutide/metformin FDC
02
Targets
GCGR (Glucagon receptor)GLP1R (GLP-1R)AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on survodutide + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on survodutide + metformin.